Belite Bio, Inc - American Depositary Shares (BLTE)
BLTE moved a median of -0.08% 30 minutes after news, and +0.08% by the close. How BLTE actually reacts to news — the realized, point-in-time move the market made, measured across 255 labeled events over the last three years with zero look-ahead.
BLTE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 30% | 219 |
| 30-min | -0.08% | 42% | 248 |
| 60-min | -0.17% | 40% | 252 |
| to close | +0.08% | 53% | 255 |
| Middle 50% of BLTE reactions | -1.49% to +0.73% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 255 |
Half of all Belite Bio, Inc - American Depositary Shares news events land between -1.49% and +0.73% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BLTE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +0.12% | 50% | +0.10% |
| Coverage initiations | 14 | +0.23% | 50% | -0.10% |
| Rating reiterations | 71 | +0.02% | 51% | +0.51% |
| Price-target raises | 10 | +0.06% | 60% | -1.16% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how BLTE ranks against every other measured name →
That’s how BLTE usually reacts — get an email when it moves on news →Email me when BLTE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BLTE's baseline. Nothing else.
Recent BLTE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 | Press release | GlobeNewswire | +0.02% | -0.81% | |
| Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences | Press release | GlobeNewswire | -0.37% | -3.55% | |
| Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences | Press release | GlobeNewswire | +1.68% | -0.04% | |
| Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 | Press release | GlobeNewswire | -0.37% | +0.07% | |
| Form 6-K BELITE BIO, INC For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | -0.37% | +0.07% | |
| Belite Bio to Participate in Four Upcoming Investor Conferences | Press release | GlobeNewswire | +1.50% | +1.43% | |
| Belite Bio to Host Virtual Commercial Day on September 2, 2026 | Press release | GlobeNewswire | +0.10% | +0.37% | |
| Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences | Press release | GlobeNewswire | +0.61% | -1.49% | |
| Form 6-K BELITE BIO, INC For: Aug 12 | SEC filing · Form 6-K | SEC EDGAR | -3.45% | -7.08% | |
| Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | -3.45% | -7.08% | |
| Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 | Press release | GlobeNewswire | -1.04% | -0.90% | |
| Form 6-K BELITE BIO, INC For: Aug 11 | SEC filing · Form 6-K | SEC EDGAR | -1.04% | -0.90% | |
| Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.81% | +1.37% | |
| Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 | Press release | GlobeNewswire | +0.00% | +1.47% | |
| Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference | Press release | GlobeNewswire | -1.34% | +1.60% | |
| Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences | Press release | GlobeNewswire | +1.63% | +4.84% | |
| Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium | Press release | GlobeNewswire | +1.63% | +4.84% | |
| Form 6-K BELITE BIO, INC For: Jun 12 | SEC filing · Form 6-K | SEC EDGAR | +1.07% | +2.66% | |
| Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 | Press release | GlobeNewswire | +1.07% | +2.66% | |
| Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | -2.06% | -7.58% | |
| Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight | Press release | PR Newswire | -0.46% | +0.40% | |
| Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | +1.94% | +0.94% | |
| Form 6-K BELITE BIO, INC For: May 20 | SEC filing · Form 6-K | SEC EDGAR | +1.94% | +0.94% | |
| Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland | Press release | GlobeNewswire | +0.00% | -2.53% | |
| Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) | Press release | GlobeNewswire | +0.00% | -4.52% | |
| Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.25% | -2.67% | |
| Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit | Press release | GlobeNewswire | +0.45% | +1.57% | |
| Prevent Blindness Declares May as Third Annual Inherited Retinal Disease and Genetic Testing Month, Offering Resources to Public and Healthcare Allies, to Help Save Sight | Press release | PR Newswire | -0.21% | -0.24% | |
| Belite Bio to Participate in Four Upcoming Investor Conferences | Press release | GlobeNewswire | -0.19% | -3.01% | |
| Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th | Press release | GlobeNewswire | -1.13% | -0.88% | |
| Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease | Press release | GlobeNewswire | -1.13% | -0.88% | |
| Form 6-K BELITE BIO, INC For: Apr 21 | SEC filing · Form 6-K | SEC EDGAR | -1.13% | -0.88% | |
| Foundation Fighting Blindness to Host United in Vision 2026 Conference in Partnership with Retina International World Congress | Press release | PR Newswire | +0.20% | -1.59% | |
| Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website | Press release | GlobeNewswire | -0.38% | +6.22% | |
| Form 20-F BELITE BIO, INC For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.38% | +6.22% | |
| Form 6-K BELITE BIO, INC For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -0.38% | +6.22% | |
| Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | -2.67% | -4.58% | |
| Belite Bio to Participate in the Leerink Global Healthcare Conference | Press release | GlobeNewswire | -2.67% | -4.58% | |
| Form 6-K BELITE BIO, INC For: Mar 02 | SEC filing · Form 6-K | SEC EDGAR | -2.67% | -4.58% | |
| Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +0.03% | +4.59% | |
| Form S-8 BELITE BIO, INC | SEC filing · Form S-8 | SEC EDGAR | +0.82% | +1.42% | |
| Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) | Press release | GlobeNewswire | -0.60% | +1.82% | |
| Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1) | Press release | GlobeNewswire | +1.58% | +2.73% | |
| Form 6-K BELITE BIO, INC For: Jan 27 | SEC filing · Form 6-K | SEC EDGAR | +1.58% | +2.73% | |
| Form 6-K BELITE BIO, INC For: Dec 02 | SEC filing · Form 6-K | SEC EDGAR | +0.03% | -1.41% | |
| Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares | Press release | GlobeNewswire | -4.74% | -5.98% | |
| Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares | Press release | GlobeNewswire | -4.74% | -5.98% | |
| Form 6-K BELITE BIO, INC For: Dec 01 | SEC filing · Form 6-K | SEC EDGAR | -10.26% | +0.67% | |
| New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease | Press release | GlobeNewswire | -10.26% | +0.67% | |
| Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | -1.88% | +2.79% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BLTE section they belong to.
Where else BLTE is measured.
BLTE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Belite Bio, Inc - American Depositary Shares's median reaction calculated?
Every labeled BLTE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 255 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of BLTE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BLTE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.